Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials
UCLA's Jonsson Comprehensive Cancer Center
Take the Jonsson Cancer Center Site Survey

JCCC Member Directory

Richard Finn, M.D.
Richard Finn, M.D.

Specialty:

Hematology
Internal Medicine
Medical Oncology

General Information:

Gender:
Male
Language(s):
English

Affiliation(s):

Physician, Department of Surgery, Dumont-UCLA Liver Cancer Center
Co-Director, JCCC Signal Transduction and Therapeutics Program Area

Education:

Fellowship:
Hematology/Oncology, UCLA School of Medicine, 2000 - 2003
Residency:
Internal Medicine, UCLA School of Medicine, 1998 - 2000
Internship:
Internal Medicine, UCLA School of Medicine, 1997 - 1998
Medical Degree:
M.D., USC School of Medicine, 1997

Certification(s):

Medical Board Certification(s):
Hematology, American Board of Internal Medicine, 2003
Medical Oncology, American Board of Internal Medicine, 2003
Internal Medicine, American Board of Internal Medicine, 2000

Contact Information:

Gastrointestinal Oncology:
(310) 206-1446 (Information and referral)
Dumont-UCLA Liver Cancer Center:
(310) 825-1412 Information and referral
(310) 206-3748 Referring physician
UCLA Oncology Center:
(310) 206-6931 Information and patient appointments
(310) 206-6909 Information and patient appointments
Phone:
(310) 829-5471 Santa Monica office
(310) 206-3180 Office
Email:

Practice Information:

Clinical Interest(s):
Biliary
Breast
Cancers of the Digestive Tract
Gastrointestinal
General Hematology
General Oncology
Hepatobiliary
Liver

Scientific Interest(s):

Dr. Richard Finn's research and clinical interests are in treating liver and breast cancer.

Selected Cancer-Related Publications:

Finn RS, Dering J, Ginther C, Wilson CA, Glaspy P, Tchekmedyian N, Slamon DJ. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat. 2007.

Butterfield LH, Ribas A, Dissette VB, Lee Y, Yang JQ, De la Rocha P, Duran SD, Hernandez J, Seja E, Potter DM, McBride WH, Finn R, Glaspy JA, Economou JS. A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. Clin Cancer Res. 2006; 12(9): 2817-25.

Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, Untch M, Rusnak DW, Spehar G, Mullin RJ, Keith BR, Gilmer TM, Berger M, Podratz KC, Slamon DJ. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 2006; 66(3): 1630-9.

Bryant JA, Finn RS, Slamon DJ, Cloughesy TF, Charles AC. EGF activates intracellular and intercellular calcium signaling by distinct pathways in tumor cells. Cancer Biol Ther. 2004; 3(12): 1243-9.

Finn RS, Slamon DJ. Monoclonal antibody therapy for breast cancer: herceptin. Cancer Chemother Biol Response Modif. 2003; 21: 223-33.